Table 1.

Demographic parameters and medications of the 4 groups of subjects

Parameters	NTN	HTN	MetS	CKD
Number of subjects	15	16	15	16
Demographic parameters
Age (y)	52 ± 11	59 ± 10	62 ± 6*	66 ± 7**
Male sex (%)	53	56	60	81
Obesity (%)	27	6	60	31
Central obesity (%)	27	13	93	44
Dyslipidemia (%)	53	81	93	56
Diabetes (%)	0	0	67	6
Microalbuminuria (%)	14	13	27	63
Medications
ASA (%)	7	56	47	44
ARBs or ACE inhibitors (%)	0	81	73	81
MR blockers (%)	0	0	7	0
Diuretics (%)	0	44	73	56
CCBs (%)	0	38	67	75
β-blockers (%)	0	25	27	31
α2-agonists (%)	0	6	13	0
Statins (%)	47	75	80	50
Fibrates (%)	0	6	7	0
CA inhibitors (%)	0	0	7	0
Insulin (%)	0	0	7	0
Insulin secretagogues (%)	0	0	20	0
Insulin sensitizers (%)	0	0	53	0

Demographic parameters and medication were assessed in normotensive subjects (NTN), and patients with hypertension (HTN) associated or not with other features of the metabolic syndrome (MetS) or with chronic kidney disease (CKD) at visit 1. Data are shown as % for categorical and as means ± SD for continuous variable. Comparisons between multiple groups were analyzed by one-way analysis of variance (ANOVA) followed by a Student–Newman–Keuls post hoc. *P < 0.05 and **P < 0.001 vs. NTN. Abbreviations: α2-agonists, α2-adrenergic receptor agonists; ACE, angiotensin-converting enzyme; ARBs, angiotensin receptor type 1 blockers; ASA, acetylsalicylic acid; β-blockers, β-adrenergic receptor blockers; CA inhibitors, cholesterol absorption inhibitors; CCBs, calcium channel blockers; MR, mineralocorticoid receptor.